LLY Eli Lilly & Co.
In the sell zone
Price has run up to the upper trend line — the level it has repeatedly stalled at.
- Lower line today
- US$713.35
- Upper line today
- US$1,209
- Position in channel
- 88%
- Trend
- Rising channel
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line
- Lower trend line
- Projected 3 months
Suggested path
Buy at or below
US$1,114
level as at 31 Aug 2026
Target
US$1,181
by 24 Sept 2026
Projected move
6.0%
gross, before costs
The lines are drawn where this stock has actually turned: 5 touches on the ceiling, 4 on the floor, each fitted to the slope that catches the most of them. Buying one average daily range below its 50-day mean, while it is still above its 200-day mean, and taking 6% has come up 783 times, 64% of them reaching the target, typically in 24 days, with price going about 7% against the entry at worst (35% in the worst case). This stock has not traded long enough to choose a plan of its own, so the levels come from the market-wide rule — derived on eight unrelated tickers and then confirmed on 87 others it was never fitted to, where it reached target 64% of the time. Treat it as the general setup applied here, not as this stock’s own record. On this stock the setup has come up 2 times so far, reaching target 50% of the time — too few to mean much on its own.
On this stock's own history these rules produced 3 settled calls, of which 3 reached target (100%), with an average best move of 9.8%. See the full record.
- Upper line touches
- 5
- Lower line touches
- 4
- Fit confidence
- 61%
- Fitted
- 2 Aug 2026
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks
- Employees
- 50,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$1.08T
- Enterprise value
- —
- Beta
- 0.51
- Avg volume
- 3.03M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 623.78-1249.45
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.